Full Text:   <1338>

CLC number: R55

On-line Access: 2010-10-05

Received: 2010-02-16

Revision Accepted: 2010-06-29

Crosschecked: 2010-08-13

Cited: 12

Clicked: 3450

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2010 Vol.11 No.10 P.762-770


FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics

Author(s):  Lei Wang, Wei-lai Xu, Hai-tao Meng, Wen-bin Qian, Wen-yuan Mai, Hong-yan Tong, Li-ping Mao, Yin Tong, Jie-jing Qian, Yin-jun Lou, Zhi-mei Chen, Yun-gui Wang, Jie Jin

Affiliation(s):  Department of Hematology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; more

Corresponding email(s):   zjuhematology@163.com

Key Words:  Acute myeloid leukemia (AML), Normal cytogenetics, Prognosis, fms-like tyrosine kinase 3 internal tandem duplication (FLT3/ITD), Nucleophosmin (NPM1), Mutation

Lei Wang, Wei-lai Xu, Hai-tao Meng, Wen-bin Qian, Wen-yuan Mai, Hong-yan Tong, Li-ping Mao, Yin Tong, Jie-jing Qian, Yin-jun Lou, Zhi-mei Chen, Yun-gui Wang, Jie Jin. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics[J]. Journal of Zhejiang University Science B, 2010, 11(10): 762-770.

@article{title="FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics",
author="Lei Wang, Wei-lai Xu, Hai-tao Meng, Wen-bin Qian, Wen-yuan Mai, Hong-yan Tong, Li-ping Mao, Yin Tong, Jie-jing Qian, Yin-jun Lou, Zhi-mei Chen, Yun-gui Wang, Jie Jin",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics
%A Lei Wang
%A Wei-lai Xu
%A Hai-tao Meng
%A Wen-bin Qian
%A Wen-yuan Mai
%A Hong-yan Tong
%A Li-ping Mao
%A Yin Tong
%A Jie-jing Qian
%A Yin-jun Lou
%A Zhi-mei Chen
%A Yun-gui Wang
%A Jie Jin
%J Journal of Zhejiang University SCIENCE B
%V 11
%N 10
%P 762-770
%@ 1673-1581
%D 2010
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1000052

T1 - FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics
A1 - Lei Wang
A1 - Wei-lai Xu
A1 - Hai-tao Meng
A1 - Wen-bin Qian
A1 - Wen-yuan Mai
A1 - Hong-yan Tong
A1 - Li-ping Mao
A1 - Yin Tong
A1 - Jie-jing Qian
A1 - Yin-jun Lou
A1 - Zhi-mei Chen
A1 - Yun-gui Wang
A1 - Jie Jin
J0 - Journal of Zhejiang University Science B
VL - 11
IS - 10
SP - 762
EP - 770
%@ 1673-1581
Y1 - 2010
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1000052

mutations of fms-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1) exon 12 genes are the most common abnormalities in adult acute myeloid leukemia (AML) with normal cytogenetics. To assess the prognostic impact of the two gene mutations in Chinese AML patients, we used multiplex polymerase chain reaction (PCR) and capillary electrophoresis to screen 76 AML patients with normal cytogenetics for mutations in FLT3 internal tandem duplication (FLT3/ITD) and exon 12 of the NPM1 gene. FLT3/ITD mutation was detected in 15 (19.7%) of 76 subjects, and NPM1 mutation in 20 (26.3%) subjects. Seven (9.2%) cases were positive for both FLT3/ITD and NPM1 mutations. Significantly more FLT3/ITD aberration was detected in subjects with French-American-British (FAB) M1 (42.8%). NPM1 mutation was frequently detected in subjects with M5 (47.1%) and infrequently in subjects with M2 (11.1%). FLT3 and NPM1 mutations were significantly associated with a higher white blood cell count in peripheral blood and a lower CD34 antigen expression, but not age, sex, or platelet count. Statistical analysis revealed that the FLT3/ITD-positive group had a lower complete remission (CR) rate (53.3% vs. 83.6%). Survival analysis showed that the FLT3/ITD-positive/NPM1 mutation-negative group had worse overall survival (OS) and relapse-free survival (RFS). The FLT3/ITD-positive/NPM1 mutation-positive group showed a trend towards favorable survival compared with the FLT3/ITD-positive/NPM1 mutation-negative group (P=0.069). Our results indicate that the FLT3/ITD mutation might be a prognostic factor for an unfavorable outcome in Chinese AML subjects with normal cytogenetics, while NPM1 mutation may be a favorable prognostic factor for OS and RFS in the presence of FLT3/ITD.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1]Baarcenai, A., Muench, M.O., Roncarolo, M.G., Spits, H., 1995. Tracing the expression of CD7 and other antigens during T- and myeloid-cell differentiation in the human fetal liver and thymus. Leuk. Lymphoma, 17(1):1-11.

[2]Baldus, C.D., Thiede, C., Soucek, S., Bloomfield, C.D., Thiel, E., Ehninger, G., 2006. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J. Clin. Oncol., 24(5):790-797.

[3]Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R., Sultan, C., 1985. Proposed revised criteria of the classification of acute myeloid leukemia. Ann. Intern. Med., 103(4):620-625.

[4]Colovic, N., Tosic, N., Aveic, S., Djuric, M., Milic, N., Bumbasirevic, V., Colovic, M., Pavlovic, S., 2007. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia. Ann. Hematol., 86(10):741-747.

[5]Döhner, K., Schlenk, R.F., Habdank, M., Scholl, C., Rücker, F.G., Corbacioglu, A., Bullinger, L., Fröhling, S., Döhner, H., 2005. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106(12):3740-3746.

[6]Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al., 2005. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med., 352(3):254-266.

[7]Fröhling, S., Schlenk, R.F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., Döhner, K., 2002. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 100(13):4372-4380.

[8]Grundler, R., Miething, C., Thiede, C., Peschel, C., Duyster, J., 2005. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood, 105(12):4792-4799.

[9]Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., Naoe, T., 2000. Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, 19(5):624-631.

[10]Huang, Q., Chen, W., Gaal, K.K., Slovak, M.L., Stein, A., Weiss, L.M., 2008. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br. J. Haematol., 142(3):489-492.

[11]Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L., Gilliland, D.G., 2002. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99(1):310-318.

[12]Kiyoi, H., Ohno, R., Ueda, R., Saito, H., Naoe, T., 2002. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene, 21(16):2555-2563.

[13]Mori, Y., Yoshimoto, G., Kumano, T., Miyamoto, T., Iino, T., Takenaka, K., Iwasaki, H., Harada, N., Kinukawa, N., Nagafuji, K., 2007. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation. Eur. J. Haematol., 79(1):17-24.

[14]Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., Misawa, S., 1996. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia, 10(12):1911-1918.

[15]Pabst, T., Mueller, B.U., Zhang, P., Radomska, H.S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., Tenen, D.G., 2001. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/ EBPα), in acute myeloid leukemia. Nat. Genet., 27(3):263-270.

[16]Rabinowich, H., Pricop, L., Herberman, R.B., Whiteside, T.L., 1994. Expression and function of CD7 molecule on human natural killer cells. J. Immunol., 152(2):517-526.

[17]Rausei-Mills, V., Chang, K.L., Gaal, K.K., Weiss, L.M., Huang, Q., 2008. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3-ITD mutation. Am. J. Clin. Pathol., 129(4):624-629.

[18]Rocnik, J.L., Okabe, R., Yu, J.C., Lee, B.H., Giese, N., Schenkein, D.P., Gililand, D.G., 2006. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood, 108(4):1339-1345.

[19]Schichman, S.A., Caligiuri, M.A., Strout, M.P., Carter, S.L., Gu, Y., Canaani, E., Bloomfield, C.D., Croce, C.M., 1994. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res., 54:4277-4280.

[20]Schlenk, R.F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., 2008. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med., 358(18):1909-1918.

[21]Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Löffler, H., Sauerland, C.M., Serve, H., Büchner, T., 2002. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100(1):59-66.

[22]Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W., Falini, B., 2005. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106(12):3733-3739.

[23]Suzuki, T., Kiyoi, H., Ozeki, K., Tomita, A., Yamaji, S., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., 2005. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood, 106(8):2854-2861.

[24]Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., 2002. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99(12):4326-4335.

[25]Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T., Schaich, M., Ehninger, G., 2006. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 107(10):4011-4020.

[26]Tse, K.F., Allebach, J., Levis, M., Smith, B.D., Bohmer, F.D., Small, D., 2002. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia, 16(10):2027-2036.

[27]Verhaak, R.G., Goudswaard, C.S., van Putten, W., Bijl, M.A., Sanders, M.A., Hugens, W., Uitterlinden, A.G., Erpelinck, CA., Delwel, R., Löwenberg, B., 2005. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood, 106(12):3747-3754.

[28]Yanada, M., Matsuo, K., Suzuki, T., Kiyoi, H., Naoe, T., 2005. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia, 19(8):1345-1349.

[29]Zheng, R., Friedman, A.D., Small, D., 2002. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood, 100(12):4154-4161.

[30]Zheng, R., Friedman, A.D., Levis, M., Li, L., Weir, E.G., Small, D., 2004. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression. Blood, 103(5):1883-1890.

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE